Respiratory

Back to articles

Long-acting muscarinic combination better than glucocorticoid combination for COPD

KEY POINT

In patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations in the previous year, use of inhaled indacaterol–glycopyrronium resulted in fewer exacerbations compared with salmeterol–fluticasone (Advair—GlaxoSmithKline), according to results of the FLAME (Effect of Indacaterol Glycopyrronium vs. Fluticasone Salmeterol on COPD Exacerbations) study published in the New England Journal of Medicine.

SOURCES

Wedzicha JA, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374:2222–34.

Donohue JF. Another choice for prevention of COPD exacerbations. N Engl J Med. 2016;374:2284–6.